A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 118
- Registration Number
- NCT05980806
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇧🇪UZ Gent, Gent, Belgium
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 220
- Registration Number
- NCT05611931
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Honor Health, Phoenix, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 13
- Registration Number
- NCT04854434
- Locations
- 🇺🇸
Christiana Care Health Services, Christiana Hospital, Newark, Delaware, United States
🇺🇸BRCR Global, Plantation, Florida, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 15
- Registration Number
- NCT04768881
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Minnesota Oncology Hematology, Minneapolis, Minnesota, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 350
- Registration Number
- NCT04607772
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸US Oncology - Oncology Associates of Oregon, Eugene, Oregon, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 330
- Registration Number
- NCT04562389
- Locations
- 🇺🇸
UAB Division of Hematology/Oncology, Birmingham, Alabama, United States
🇺🇸UCLA - Satellite Site, Encino, California, United States
🇺🇸City of Hope, Duarte, California, United States
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 112
- Registration Number
- NCT04562870
- Locations
- 🇺🇸
The Oncology Institute of Hope and Innovation, Pasadena, California, United States
🇺🇸Illinois Cancer Specialist, Niles, Illinois, United States
🇺🇸Texas Oncology - Northeast Texas, Tyler, Texas, United States
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- Drug: Selinexor (combination therapy)Drug: Placebo matching for Selinexor (combination therapy)Drug: Rituximab (combination therapy)Drug: Gemcitabine (combination therapy)Drug: Dexamethasone (combination therapy)Drug: Cisplatin (combination therapy)Drug: Selinexor (continuous therapy)Drug: Placebo matching for Selinexor (continuous therapy)
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 501
- Registration Number
- NCT04442022
- Locations
- 🇺🇸
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸The Oncology Institute (TOI) Clinical Research, Cerritos, California, United States
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 74
- Registration Number
- NCT04421378
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of California, San Francisco, California, United States
🇺🇸University of Southern California (USC Norris Comprehensive Cancer Center and LAC+USC Medical Center), Los Angeles, California, United States
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 141
- Registration Number
- NCT04414475
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇬🇷Theageneion Cancer Hospital, Thessaloniki, Greece
🇮🇱Rabin Medical Center (Beilinson Hospital), Petah Tikva, Israel